Abstract Adjuvant hormonal therapy significantly improves long-term survival of breast cancer patients with hormone receptor-positive disease. Despite the proven clinical efficacy of tamoxifen and aromatase inhibitors, many breast cancer survivors either fail to take the correct dosage at the prescribed frequency (adherence) or discontinue therapy (persistence). This systematic review aims to: (1) determine the prevalence of adherence and persistence to adjuvant hormonal therapy among breast cancer survivors in clinical practice, and (2) identify correlates of adherence and persistence. We searched Medline, PubMed, PsycINFO, and CINAHL for studies that measured rates and/or correlates of adherence and/or persistence to adjuvant hormonal therapy. Studies were reviewed in a multistep process: (1) the lead author screened titles and abstracts of all potentially eligible studies; (2) each coauthor reviewed a random 5 % sample of abstracts; and (3) two sets of coauthors each reviewed half of all ''maybe'' abstracts. Any disagreements were discussed until consensus was reached. Twenty-nine studies met inclusion criteria. Prevalence of adherence ranged from 41 to 72 % and discontinuation (i.e., nonpersistence) ranged from 31 to 73 %, measured at the end of 5 years of treatment. Extremes of age (older or younger), increasing out-ofpocket costs, follow-up care with a general practitioner (vs. oncologist), higher CYP2D6 activity, switching from one form of therapy to another, and treatment side effects were negatively associated with adherence and/or persistence.
As evidence of improvement in survival from these treatments has mounted, researchers have become interested in adherence to adjuvant hormonal therapy as a possible major contributor to differences in therapeutic effect [9] [10] [11] . Despite the proven clinical efficacy of tamoxifen and aromatase inhibitors, evidence from clinical trials suggests 8-28 % of patients do not complete treatment as recommended [2, 4, 5, 12] . Previous narrative reviews have similarly found that 10-50 % of breast cancer survivors in both clinical trial and clinical practice settings either fail to take the correct dosage at the prescribed frequency (i.e., adherence) or discontinue therapy (i.e., persistence), thus increasing their risk for new and recurrent breast cancers [13] [14] [15] [16] [17] [18] . These reviews, however, have not focused exclusively on treatment delivered in routine clinical settings, instead relying on data from randomized controlled trials of treatment efficacy, where adherence to recommended treatment is not the primary outcome of interest. Further, most adjuvant treatment is delivered in clinical practice settings, rather than in clinical trials, where support from ancillary personnel, more frequent clinic visits, and patient motivation to participate in clinical trials is likely to positively affect adherence. It is important to better understand treatment adherence in routine clinical settings where patients may not be as closely monitored so that the survival benefits of adjuvant hormonal therapy are realized by patients receiving treatment under ''real world'' conditions. Identifying a benchmark measure of adherence in clinical practice could provide a basis for further research and intervention development to promote treatment adherence, improve the coordination of survivorship care, and ultimately reduce mortality.
To address the gap in the literature regarding adherence in routine clinical settings (vs. clinical trials), we conducted a systematic review of the adjuvant hormonal therapy literature in clinical practice settings, with the specific aims to: (1) determine the prevalence of adherence and persistence to adjuvant hormonal therapy among breast cancer survivors, and (2) identify correlates of adherence and persistence.
Methods
Search methods were conducted according to the Preferred Reporting of Systematic Reviews and Meta-Analysis (PRISMA) Statement guidelines [19] . With the assistance of a health sciences librarian, we searched Medline searched May 11, 2012) for studies that measured prevalence and/or correlates of adherence and/or persistence to adjuvant hormonal therapy among breast cancer survivors in the clinical practice setting from 1998 through 2012. Scopus (via Elsevier; searched May 16, 2012 ) was used to search the bibliographies of selected studies for additional relevant cited articles. The search was limited to studies after 1998 because of the Early Breast Cancer Trialists' Collaborative Group's publication of their review that demonstrated the efficacy of tamoxifen in the prevention of breast cancer recurrence in randomized trials [20] . Search terms included nonadherence or non-adherence or adherence, continuance or persist* or complian* or discontinu*, estrogen antagonists, tamoxifen, and aromatase inhibitors, and were adapted according to the database searched. Search strategies for each database are listed in the Appendix.
Inclusion and exclusion criteria
Studies were considered eligible for review if they (1) were written in English; (2) were published in a peer-reviewed journal in 1998 through 2012; (3) reported data from a primary study (i.e., not a review, editorial, or commentary); (4) included female breast cancer survivors who were prescribed and initiated adjuvant hormonal therapy after completing primary treatment for breast cancer; and (5) measured or assessed the prevalence and/or correlates of adherence and/or persistence to treatment in clinical practice settings. Adherence was defined as the degree of conformity to provider prescription with respect to timing, dosage, and frequency of day-to-day medication use. Persistence was defined as the duration from initiation to discontinuation of therapy [21] . Adjuvant hormonal therapy included both selective estrogen-receptor modulators (e.g., tamoxifen, raloxifene) and aromatase inhibitors (e.g., anastrozole, letrozole, exemestane). Studies that examined adherence and/or persistence to extended hormonal therapy or exclusively after therapy switches, in predominantly male breast cancer patient populations, in women with ductal carcinoma in situ (DCIS), for the treatment of metastatic disease, or in study populations without a definitive breast cancer diagnosis were excluded.
Studies were screened and reviewed in a collaborative, multi-step process. First, the lead author screened the titles and abstracts of all potentially relevant articles to determine eligibility. Abstracts were coded as ''no'' or ''maybe'' for further inclusion. For quality assurance, each coauthor independently reviewed the titles and abstracts of a random 5 % sample. Abstracts coded as ''no'' by all authors were excluded from further review; abstracts coded as ''maybe'' by any author were discussed. Two pairs of coauthors reviewed half of all ''maybe'' abstracts. Disagreements occurred in less than 5 % of all articles. Any disagreements were discussed until consensus was reached.
Completeness of reporting
The International Society of Pharmacoeconomics and Outcomes Research (ISPOR) has published a checklist for studies of medication compliance and persistence that use administrative databases [22] . The checklist provides a list of items that should be included in reporting adherence studies, with the ultimate aim of improving the consistency and quality of adherence and persistence analysis. We assessed the completeness of reporting of studies included in our review using selected variables from the checklist, with particular emphasis on outcome variables, methodology, statistical analysis, limitations, and generalizability. We recorded whether studies adhered to these criteria by scoring each item as ''YES (Y),'' ''NO (N),'' or ''INFERRED (I).''
Results
Our search strategy identified 616 potentially eligible citations, of which 30 (29 studies reported in 30 articles, 4.9 %) met inclusion criteria (see Fig. 1 for PRISMA flow diagram). Although the outcomes were not uniformly defined, studies measured adherence (11) [10, [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] , persistence (9) [33] [34] [35] [36] [37] [38] [39] [40] [41] , and both (9) [9, 11, [42] [43] [44] [45] [46] [47] [48] . Twenty-four [9, 11, 23-29, 31-41, 43, 44, 46, 48] studies also examined correlates of persistence and/or adherence.
Fifteen [9-11, 23, 28, 31, 32, 40, 42-48] studies measured the prevalence of adherence and/or persistence using administrative or prescription claims data linked with medical data, while eight [25-27, 29, 37-39, 41] reviewed medical records or existing hospital databases/registries, and six [24, 30, [33] [34] [35] [36] relied on patient self-report. Four [33] [34] [35] 39] were prospective studies.
Adherence to adjuvant hormonal therapy was most often defined as a medication possession ratio (MPR) of C80 % [9-11, 23, 27-29, 31, 32, 42-48] . To be considered adherent, prescription users must have evidence of a supply of medication for more than 80 % of a given time period (usually measured in 1 year intervals). Persistence was generally defined as continuous use of tamoxifen or aromatase inhibitors, with few gaps in treatment or prescription refills. The minimum treatment gap allowable to remain persistent ranged from 45 to 180 days [9, 11, 37, 40, 42-44, 47, 48] . A small percentage of studies measured persistence as self-reported continuous medication use at each follow-up interview [33] [34] [35] . Adherence and persistence were labeled in a variety of ways (e.g., adherence, nonadherence, persistence, nonpersistence). To avoid the confusion of multiple terms to describe the same phenomena, we converted authors' labels as either prevalence of adherence or prevalence of discontinuation (i.e., nonpersistence).
Prevalence of adherence and discontinuation
As shown in Table 1 , adherence to and/or discontinuation of adjuvant hormonal therapy varied widely, as did the methodology of each study. The prevalence of adherence ranged from 41 to 88 % among tamoxifen users [9, 23-25, 27, 29-31, 45, 46] and 50-91 % for aromatase inhibitors [27, 28, 30, 31, 42, [44] [45] [46] . Studies that examined both forms of therapy together reported adherence rates of 46-100 % [11, 27, 32, 43, 47] . Similarly, mean or median MPR ranged from 58 to 93 % [9, 10, 23, 47] , measured at various time intervals. When limited to studies that measured adherence over periods greater than 4 years, prevalence ranged from 41 to 72 % for all forms of therapy [11, 23, 30, [45] [46] [47] .
Among tamoxifen users, the percentage of women who discontinued treatment ranged from 15 to 20 % in the first year of therapy [37, 39, 40, 45, 48 ] to 31-60 % at the end of year 5 [9, 37, 40, 45] . In women exclusively taking aromatase inhibitors, discontinuation ranged from 5 to 25 % during the first 2 years of therapy [42, 44, 45] . In studies that examined both tamoxifen and aromatase inhibitors (i.e., there was no distinction between treatment with tamoxifen and treatment with aromatase inhibitors), discontinuation rates ranged from 32 to 73 % at the end of 5 years of treatment [11, 26, 40, 41, 46] . Prospective selfreport studies describe discontinuation rates of 21, 15, and 31 % at the end of 27-, 33-, and 63-month study periods, respectively [33] [34] [35] . These studies examined treatment with tamoxifen alone.
Factors associated with adherence and discontinuation
Overall, factors associated with adherence and persistence to adjuvant hormonal therapy among breast cancer survivors have been largely unexamined to date. Similar to the prevalence of adherence and persistence, correlates were studied and framed in a variety of ways (i.e., as either factors associated with nonadherence, adherence, persistence, or nonpersistence). Because of the general agreement between studies in how adherence and persistence were defined (MPR C 80 % and minimal gaps in treatment, respectively), we summarized available evidence based on the assumption that there was adequate construct validity among studies. For example, a variable positively associated with nonadherence was also considered to be negatively associated with adherence.
As demonstrated in examined in a single study, or were found to have no significant associations. The only consistent (i.e., measured in two or more studies and no study reported no effect), statistically significant factors associated with hormone therapy use were cytochrome P450 2D6 (CYPD26) activity and switching from one form of therapy to another. Women with higher levels of CYPD26 were less likely to be adherent to and/or continue treatment [29, 39] . Similarly, patients who switched hormonal therapies (e.g., switched to an aromatase inhibitor after 2-3 years of tamoxifen) were less likely to adhere to treatment [28, 32] . All other variables either had mixed findings or no effect. Extremes of age (i.e., older or younger), increasing out-of-pocket costs, follow-up care with a general practitioner (vs. cancer specialist), and treatment side effects were largely negatively associated with adherence [9, 11, 23, 25, 26, 28, 31, 33, 35-37, 40, 41, 44, 46] . In contrast, taking more medications at baseline, referral to an oncologist, and earlier year at diagnosis were generally positively associated [11, 23, 28, 34, 35, 46] . Some studies reported no effect for each of these variables. Few studies examined psychosocial or behavioral constructs associated with medication adherence. Kahn [36] found that making treatment decisions alone or having less than desired social support was negatively associated with persistence. Likewise, Huiart [48] reported that women with reported low social and/or material support were more likely to discontinue treatment. Other studies suggested lower perceived need for medication and negative decisional balance scores [24, 34] were negatively associated Studies labeled adherence and/or persistence outcomes in a variety of ways (e.g., % adherent, % nonadherent, % persistent, or % nonpersistent). To avoid the confusion of multiple terms to describe the same phenomena, we converted authors' labels to either prevalence of adherence or prevalence of discontinuation. Nonadherence and persistence rates reported in studies were inverted to arrive at prevalence of adherence and discontinuation, respectively b Historical cohort study (also known as a retrospective cohort study) refers to studies that identified a cohort of breast cancer cases prescribed and/or treated with adjuvant hormonal therapy from existing information before the time during which they were at risk for nonadherence or discontinuation, and collected data on adherence and persistence outcomes through medical record or prescription claims databases [82] Using books/magazines in treatment decision making * with adherence and/or persistence. Each of these variables, however, was only examined in one study.
Completeness of reporting
In studies that utilized prescription or medical claims databases, all reported data sources, used standard methodology (i.e., MPR or gaps method), and provided explicit definitions of adherence and/or persistence (Table 3) . Studies were more variable with respect to efforts to address selection bias (e.g., propensity scoring) or potential confounders; efforts to address bias were implied by 13 [9-11, 23, 28, 31, 32, 40, 43-46, 48] studies that used adjusted multivariable analysis. None of the studies discussed how MPR values greater than 1 or negative gap values (i.e., study participant had more medication than necessary to adequately cover the time period under review) were handled in statistical analysis, and only a few reported how changes in medications were analyzed. Few [28, 30, 44, 46] studies explicitly addressed external validity.
Discussion
Our review of adherence and persistence to adjuvant hormonal therapy among breast cancer survivors in 29 nonclinical trial settings demonstrates that treatment adherence is suboptimal in these settings, and may be worse than clinical trials that evaluate the efficacy of treatment regimens. When combining the proportion of breast cancer survivors who either discontinued treatment or were nonadherent, more than two-thirds of survivors do not complete 5 years of adjuvant hormonal therapy as recommended [9, 11, 26, 30, 35, 37, 40, 46, 47] . In randomized controlled trials, early discontinuation of tamoxifen ranged from 13-28 % and 8-24 % for aromatase inhibitors [2, 4, 5, 12] . Treatment discontinuation in the ''real world,'' however, ranged from 31 to 73 %, suggesting there may be important differences in how treatment is delivered in clinical practice. Away from the confines of clinical trial protocols, adherence to, and persistence with, adjuvant hormonal therapy may not be as closely monitored, leaving more opportunity for patients to skip doses or stop therapy. Discontinuation or intermittent use of therapy is concerning because high levels of nonadherence may reduce the benefits of treatment observed in clinical trials. The discrepancy in the ranges of discontinuation rates reported in clinical practice settings (31-73 %) compared with clinical trials (8-28 %) may be an indication of the differences in provider support and treatment delivery mechanisms. As the Institute of Medicine's (IOM) report on cancer survivorship reveals, the lack of clear guidelines for caring for patients with a history of cancer creates wide variation in how care is delivered [49] . Once patients complete ''active cancer treatment'' (i.e., some combination of surgery, radiation, chemotherapy), they may be unclear [49] , demonstrates that lack of coordination in the transition to survivorship care may compromise the utility of adjuvant hormonal therapy. Our review revealed that little is known about the factors associated with continued use of adjuvant hormonal therapy, and few of the correlates studied to date are modifiable. This finding is relatively consistent with a literature review on the predictors of adherence to tamoxifen as both adjuvant therapy and chemoprevention [52] , which found that sociodemographic variables such as extremes of age, non-white ethnicity, socioeconomic status, marital status, and education are associated with treatment adherence. Although demographic and treatment-related factors may help identify target populations in which to promote adherence, they do not identify factors that could be used to modify behavior. We found very few studies that examined modifiable factors, and those that did included only a single factor. Lower perceived necessity of treatment, perception of less than optimal role in the treatment decision-making process, low social and/or material support, and lower decisional balance scores were negatively associated with tamoxifen adherence [24, 34, 36, 48] . Preliminary findings from the Breast Cancer Quality of Care (BQUAL) Study measuring factors associated with initiation of hormonal therapy also suggests that patients with negative beliefs about the efficacy of treatment were less likely to initiate treatment. Patients that rated the quality of patient/physician communication more favorably, reported treatment decision making to be easier, and held positive beliefs about treatment efficacy were more likely to initiate treatment [53] . In addition, a recent study of factors associated with tamoxifen interruption reported that patients given the opportunity to ask questions about treatment at diagnosis were less likely to have treatment interruptions [54] . With such limited evidence, a critical need in this area is to further identify modifiable determinants that influence adherence in order to develop behavioral interventions to improve it.
A consistent finding in the literature is that treatment side effects are strongly associated with adherence to adjuvant therapy. Both qualitative and quantitative studies report that side effects (e.g., menopausal symptoms, arthralgia) are cited as barriers to continued treatment [33, 35, 36, 41, [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] . Finding ways to ameliorate symptoms may be a way to increase long-term adherence. At present, we have limited evidence-based strategies for reducing symptoms associated with long-term, follow-up treatment.
Results from studies evaluating alternative clinical strategies (e.g., Vitamin E or black cohosh supplements for hot flashes) are inconclusive [56, [65] [66] [67] . There is some limited evidence on how to effectively manage menopausal symptoms in breast cancer patients using various coping and self-management strategies, as well as several selfmanagement interventions in breast cancer survivors that have been shown to improve coping skills and self-regulatory behavior for a variety of survivorship concerns [68] [69] [70] [71] [72] [73] [74] . Although these studies are not hormone therapy specific, they suggest that managing menopausal symptoms requires a complex coordination of care, and that survivors' self-management skills can potentially ease side effect burden. An intervention focused on self-management of side effects could potentially reduce the prevalence of nonadherence to and discontinuation of treatment. Others have suggested that health systems interventions utilizing oncology and/or advanced practice nurses may provide patients with the necessary support to achieve treatment completion [75] [76] [77] [78] [79] . The current lack of such interventions represents a missed opportunity for health promotion.
Our review may be the first to establish a benchmark measure of adherence to adjuvant hormonal therapy among breast cancer survivors in exclusively clinical practice settings; however, it is limited in several ways. The wide variation in reported prevalence ranges from observational studies underscores potential differences in data collection and quality and highlights the need for better summary effect size estimates. Adherence in clinical practice is often measured using a variety of indirect methods (e.g., pill count, self-report, patient diaries), potentially leading to significant variation in end results.
The majority of studies included in our review indirectly measured treatment adherence by analyzing large prescription and medical claims databases. While these data sources may provide researchers with an easy and objective measure of adherence, this methodology has limitations. First, when using large population-based administrative databases, there exists significant potential for data overlap. Many of the studies included in our review used the same or overlapping databases; thus, their estimates may vary based on inclusion criteria and other considerations. Second, prescription refill does not guarantee a patient ingests medication as directed, thus potentially over-estimating the prevalence of adherence. Our assessment of studies using selected items from the ISOPR checklist [22] revealed that the majority of studies either failed to consider or failed to report efforts to reduce potential biases associated with this type of data. Many of the studies also do not report on issues affecting external validity, leaving questions of study generalizability unanswered. Several of the prescription databases reflect European or predominantly insured, white American populations, thereby excluding a large proportion of breast cancer survivors. This is especially concerning given that minority and low-income women are less likely to be treated with and/or initiate guideline recommended adjuvant systemic therapies [80, 81] .
In order to effectively move forward with intervention development aimed at promoting treatment adherence and improving the coordination of survivorship care, research must move beyond registry based data sources that contain limited information on patient characteristics so that modifiable factors associated with adherence can be identified. Factors are likely to be from a myriad of influencing sources-from a survivor's own perception of treatment to system-related factors involved in the coordination of survivorship care. Identifying and targeting such factors may ultimately promote treatment adherence, and thereby reduce breast cancer recurrence and mortality.
